OmniAb (OABI) Q2 2026 Earnings Call Transcript

OmniAb reported Q2 revenue of $13.4M (vs. $3.9M in Q2’25) driven by higher milestone revenue, and reduced its net loss to $5.9M ($0.05/share) from $15.9M ($0.15/share). Management raised FY2026 revenue guidance to $32M–$36M (from $28M–$33M) and increased year-end cash guidance to $37M–$41M, supported by milestone progression and a $52M cash position at June 30, 2026. On the pipeline/innovation front, 2 programs moved into Phase III and remaining contracted clinical-stage milestone payments total ~$340M, while xPloration instrument sales rose to 2 units (4 in the field) and OmniDeep leverages AI/ML for hit discovery.

Analysis

The near-term market read-through is not the higher revenue guide; it is that OABI is starting to show the first signs of a multi-engine model. Milestones are still the dominant driver, but the important second-order effect is that each late-stage transition increases the probability-weighted royalty stack, which is what can re-rate the name from a lumpy services/tooling story into a durable cash-collection platform. Cash burn is still a real constraint, but the runway looks serviceable enough that financing risk should not dominate unless milestone cadence slips materially.

Winners are the large-pharma partners with optionality on novel targets: JNJ, MKKGY, TEVA and IMVT all get a read-through that the platform is producing assets worth advancing, which should support continued spending on discovery tools. The more interesting competitive effect is on other antibody-enablement vendors: if xPloration placements expand, OABI can pull a consumables/software annuity lever that has much better gross margin than one-off instrument sales, but the base is too small to call a platform shift yet. The current setup is still highly partner-concentrated, so a single program slip could reverse sentiment quickly.

The contrarian miss is that the stock may be overinterpreting milestone growth as recurring growth. The key falsifier over the next 1-3 months is a weak Analyst Day on October 1/6: if management cannot quantify xPloration utilization, repeat orders, or meaningful new partner starts, the market will likely fade the optimism and reprice the story back to a binary biotech-services multiple. Over 6-18 months, the upside case requires royalties, not just milestones; without that, this remains a well-run but still fragile commercialization story.

Key Decisions for Investors

• Initiate a small tactical long in OABI common into the October Analyst Day, but size it as a catalyst trade rather than a core holding; thesis works if the company shows visible xPloration repeatability and new partner intake.
• Hedge the long with a short XBI or IBB basket position over the next 4-8 weeks to isolate idiosyncratic catalyst risk from broad biotech beta.
• If OABI rallies aggressively into Analyst Day, trim 30-50% on strength unless management gives hard evidence of instrument follow-on demand or consumables pull-through; otherwise the move is likely front-running rather than fundamental.
• Watch IMVT and TEVA updates as indirect catalysts for OABI; if either program is delayed or underwhelms, reduce exposure because OABI's forward milestone stack is more fragile than the market may assume.
• Do not add on the basis of revenue guidance alone; only increase if the company shows concrete xPloration deployment metrics or fresh clinical entrants, which would extend the 1-3 month upside window.